Structure Therapeutics (GPCR) to Release Quarterly Earnings on Thursday

Key Points

• Structure Therapeutics is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.28) per share.
• The company previously reported a loss of ($0.36) EPS in its last earnings release, falling short of the consensus estimate.
• Structure Therapeutics has seen a range in stock price from a one-year low of $13.22 to a high of $45.37 and currently has a market cap of approximately $935.22 million.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Structure Therapeutics to post earnings of ($0.28) per share for the quarter.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08). On average, analysts expect Structure Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $16.31 on Thursday. The firm has a market capitalization of $935.22 million, a price-to-earnings ratio of -18.75 and a beta of -1.89. Structure Therapeutics has a one year low of $13.22 and a one year high of $45.37. The company has a 50 day moving average price of $20.13 and a 200 day moving average price of $22.05.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on GPCR shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, June 23rd. JMP Securities restated a "market outperform" rating and set a $89.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd. Citigroup began coverage on Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, HC Wainwright decreased their target price on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a report on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has an average rating of "Buy" and an average target price of $76.17.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.